Technology Bundle ID

Cancer Therapies Using Engineered Monomeric Fc Molecules

Lead Inventors
Dimiter Dimitrov (NCI)
Tianlei Ying (NCI)
Development Status
Discovery (Lead Identification)

The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies.

Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small size and other unique properties. However, compared with full-size antibodies, these antibody fragments lack the ability to bind to some Fc receptor and have reduced half-lives.

NCI scientists have developed small (∼27 kDa) antibody fragments that are potentially useful for therapeutic development.  These are monomeric IgG fragment (mFc) compositions; they have long half-lives, are functional (pH dependent binders of neonatal Fc receptor - FcRn); soluble, and they express in E. coli efficiently.  The molecules may serve as a platform for development of engineered mFc-based antibodies and fusion proteins with therapeutic applications: the smaller size may allow for superior access to targets and tissues compared to full sized mAbs and larger fragment-based therapeutics, while also retaining important functional characteristics. The IgG Fc is a dimer of two constant domains (CH2-CH3 chains). The Fc has a long half-life, which makes it promising as a candidate for engineering antibody therapeutics.  

Commercial Applications

Therapeutics - human and veterinary, engineered antibody and fusion proteins.

Competitive Advantages
  • Smaller size results in reduced steric hindrance
  • Increased therapeutic efficiency

Request More Info

Licensing Contact: